Ali M Harandi Selected Research

glycoprotein D-herpes simplex virus type 2

6/2012	Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
12/2005	CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ali M Harandi Research Topics

Disease

19	Infections 01/2021 - 04/2001
9	Herpes Genitalis (Genital Herpes) 01/2016 - 01/2003
5	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2016 - 12/2005
3	Human Influenza (Influenza) 01/2021 - 09/2012
3	Communicable Diseases (Infectious Diseases) 03/2010 - 04/2003
2	COVID-19 01/2022 - 01/2021
2	Cutaneous Leishmaniasis 03/2020 - 01/2018
2	Hypersensitivity (Allergy) 01/2018 - 01/2016
2	Tuberculosis (Tuberculoses) 09/2015 - 03/2010
2	Inflammation (Inflammations) 12/2009 - 04/2001
2	Reinfection 01/2003 - 04/2001
1	Syphilis 01/2021
1	Gonorrhea 01/2021
1	Vesicular Stomatitis 12/2017
1	Cytopenia 12/2017
1	Viremia 12/2017
1	Whooping Cough (Pertussis) 09/2015
1	Malaria 03/2010
1	Acquired Immunodeficiency Syndrome (AIDS) 03/2010
1	Meningococcal Meningitis 02/2010
1	Pneumonia (Pneumonitis) 10/2009
1	Body Weight (Weight, Body) 10/2009
1	Virus Diseases (Viral Diseases) 05/2009
1	Cholera 04/2003

Drug/Important Bio-Agent (IBA)

14	VaccinesIBA 01/2021 - 04/2003
7	Proteins (Proteins, Gene)FDA Link 03/2020 - 06/2006
6	OligodeoxyribonucleotidesIBA 10/2009 - 01/2003
5	Glycoproteins (Glycoprotein)IBA 01/2016 - 06/2008
5	DNA (Deoxyribonucleic Acid)IBA 12/2005 - 04/2003
4	AntibodiesIBA 01/2021 - 04/2001
4	CPG-oligonucleotideIBA 12/2009 - 01/2003
3	AntigensIBA 01/2021 - 04/2003
3	Cholera ToxinIBA 10/2009 - 04/2003
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2018
2	glycoprotein D-herpes simplex virus type 2IBA 06/2012 - 12/2005
2	Myeloid Differentiation Factor 88IBA 06/2008 - 06/2008
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2022
1	NucleoproteinsIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	CytokinesIBA 01/2018
1	Adenosine DeaminaseIBA 01/2018
1	Viral VaccinesIBA 01/2016
1	poly(I).poly(c12,U) (ampligen)IBA 01/2016
1	Immunoglobulin A (IgA)IBA 01/2016
1	Immunoglobulin G (IgG)IBA 01/2016
1	Poly IIBA 01/2016
1	Poly I-CIBA 01/2016
1	Neutralizing AntibodiesIBA 01/2016
1	Hemagglutinins (Hemagglutinin)IBA 09/2012
1	Vaccine AdjuvantsIBA 03/2010
1	Membrane Proteins (Integral Membrane Proteins)IBA 10/2009
1	OvalbuminIBA 10/2009
1	alpha-galactosylceramideIBA 05/2009
1	CXC ChemokinesIBA 06/2006
1	A-Form DNA (A-DNA)IBA 12/2005
1	DNA VaccinesIBA 12/2005
1	Bacterial DNAIBA 07/2004
1	Thymidine KinaseIBA 04/2001

Therapy/Procedure

3	Immunotherapy 03/2005 - 04/2003
1	Intranasal Administration 09/2012
1	Intravaginal Administration 06/2008
1	Mucosal Administration 06/2006